Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
30 lessons
11mGHRP-6 is the original growth hormone-releasing peptide, a synthetic hexapeptide from 1984 that works on the ghrelin receptor. It reliably raises growth hormone in people, which is why endocrinologists used it as a diagnostic test. What it has never had is a trial showing it improves body composition, recovery or any clinical outcome.
16mGlutathione is a small antioxidant your cells already make. That biological role does not automatically make every supplement or IV drip effective. Here is what it is, how it works, and what human studies actually show, including the limits and risks.
11mFollistatin 344 is sold online as a muscle-building peptide. It is not a peptide: at 344 amino acids it is a protein. No published human trial has tested the injected product, the only follistatin-based drug to reach randomized trials grew muscle without improving function, and lab testing of black-market vials found most of them were not what the label said.
9mNAD+ is essential to cells. That does not make every NAD+ treatment effective. A practical guide to IV claims, oral precursors and what human studies actually measured.
9mRetatrutide is Lilly's investigational GIP, GLP-1 and glucagon receptor agonist. Understand the trial findings, how it differs from approved medicines, and why it is not available by prescription.
8mPT-141 is the research name for bremelanotide, FDA-approved in 2019 as Vyleesi for low sexual desire in premenopausal women. Here's how it works, what the trials and label say about side effects, who it isn't approved for, and why research-grade PT-141 isn't the same product.
9mTirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea). Here's what it is, what the trials showed, how it compares with semaglutide and retatrutide, and how to get evaluated by a licensed clinician.
6mARA-290 (cibinetide) explained: the EPO-derived peptide studied for small fiber neuropathy, what Phase 2 trials found, side effects, and FDA status.
10mSS-31 is elamipretide, a mitochondria-targeting peptide. FDA approved it in 2025 as Forzinity for one rare disease. Trials in other conditions mostly missed their main goals, and research vials are not the approved drug.
7mTwo of Lilly's next obesity drugs work in completely different ways. Here's how eloralintide (amylin) and retatrutide (triple agonist) compare on the published data.
9mPhase 3 data on retatrutide side effects, in plain English: how often nausea, diarrhea, dysesthesia (skin burning), low blood pressure and injection-site reactions showed up by dose, and what the trials don't tell you.
9mGLP-1s can change sleep and mood in both directions. The pattern usually comes down to dose timing, appetite changes, side effects, and the bigger metabolic picture.
11mEloralintide is Eli Lilly's once-weekly selective amylin receptor agonist. It produced up to 20.1% average weight loss at 48 weeks in Phase 2, and up to 23.3% when paired with tirzepatide. It is not approved anywhere, and its Phase 3 program will not read out before 2028.
8mCagrilintide is the amylin half of CagriSema. Here's the dosing map people actually search — 2.4 mg weekly combo context, monotherapy signal, and how not to cross-titrate with eloralintide.
7mAmylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
7mMonthly conjugates can pack a bigger post-dose GI window. Here's how to think about MariTide tolerability using Phase 2 lessons — without fear content.
8mRetatrutide's hype is not just about weight loss. The bigger story is the way a triple agonist can feel different, from warmth and energy expenditure to the GI side effects that shape adherence.
9mClinical trials show the headline results. Real-world data shows what happens after the first prescription, after the side effects, and after people try to stay on therapy long enough to benefit.
8mGLP-1 receptor agonists cause nausea in up to 44% of users and it is the top reason for discontinuation. Here is what the research shows about BPC-157 as a potential gut protectant, and where the evidence stops.
10mEpitalon is a lab-made four-amino-acid peptide based on a pineal gland extract. It lengthens telomeres in cell studies, but human evidence is small and old. It is not FDA approved, and since October 2026 it is one of six peptides in an HHS compounding policy.
8mAOD-9604 is a synthetic fragment of human growth hormone designed specifically to stimulate fat breakdown without the glucose or IGF-1 side effects of full HGH. Here's how it works and who it's for.
8mA Stanford AI tool screened 2,600 uncharacterized peptides and identified BRP — a 12-amino acid molecule that cuts food intake by up to 50%, promotes fat burning, and avoids the nausea, constipation, and muscle loss common with GLP-1 drugs. Here's what the research actually shows.
11mIGF-1 LR3 is a lab-modified copy of the IGF-1 hormone, built in 1992 as a research reagent. A 2026 review places it in the tier with no peer-reviewed human studies at all. It is not FDA approved, is regulated as a biologic rather than a peptide, and is prohibited in sport.
9mMOTS-c — a peptide synthesized inside your own mitochondria — is now in Phase 2a human trials for prediabetes. Early data suggests it improves insulin sensitivity and metabolic flexibility without the side effects of pharmaceutical interventions.
9mMOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. It has strong mouse data, one recruiting placebo-controlled human trial and no FDA approval. In October 2026 HHS added it to an interim compounding policy.
12mRetatrutide is Lilly's investigational GIP/GLP-1/glucagon triple agonist. This hub covers what it is, what the trials actually reported about dosing and weight loss, how vial math works, where approval stands, and links to every retatrutide guide on PeptIQ.io.
12mRetatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
11mExplore how Semaglutide has revolutionized weight management through GLP-1 receptor agonism.
8mDiscover how AOD-9604 targets fat metabolism specifically, offering a focused approach to body composition.
9mLearn about common peptide side effects, how to minimize them, and when they require attention.
Also available at /blog for legacy links.